WHAT IS CLAIMED IS:

1. Form B polymorph of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione.

2. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least three peaks selected from the group consisting of 5.5, 7.1, 9.3, 16.5, and 19.0 ˚2θ ± 0.2 ˚2θ.

3. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 5.5, 9.3, and 19.0 ˚2θ ± 0.2 ˚2θ.

4. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 9.3, 16.5, and 19.0 ˚2θ ± 0.2 ˚2θ.

5. The polymorph of claim 1, characterized by one or more of the following:

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 5.5, 9.3, 16.5, and 19.0 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 5.5, 7.1, 9.3, and 19.0 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 5.5, 7.1, 9.3, 16.5, 19.0, and 22.3 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising a peak at 5.5 ˚2θ ± 0.2 ˚2θ and at least four peaks selected from the group consisting of 7.1, 8.7, 9.3, 13.8, 16.2, 16.5, 17.2, 19.0, and 22.3 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 5.5, 7.1, 8.7, 9.3, 13.8, 16.2, 16.5, 17.2, 19.0, and 22.3 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 5.5, 7.1, 8.7, 9.3, 13.8, 15.8, 16.2, 16.5, 17.2, 18.5, 19.0, 19.3, 22.3, 23.1, 23.4, 23.7, 26.2, 27.3, 27.9, and 30.1 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising a peak at 5.5 ˚2θ ± 0.2 ˚2θ and at least two peaks selected from the group consisting of 7.1, 8.7, 9.3, 13.8, 16.2, 16.5, 17.2, 19.0, and 22.3 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising a peak at 5.5 ˚2θ ± 0.2 ˚2θ and at least two peaks selected from the group consisting of 7.1, 9.3, 16.5, and 19.0 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising a peak at 5.5 ˚2θ ± 0.2 ˚2θ and at least three peaks selected from the group consisting of 7.1, 8.7, 9.3, 13.8, 16.2, 16.5, 17.2, 19.0, and 22.3 ˚2θ ± 0.2 ˚2θ.

6. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, substantially as shown in Figure 2.

7. The polymorph of any one of claims 1-6, characterized by a DSC thermogram comprising an endotherm onset at about 307 °C.

8. The polymorph of claim 7, characterized by a DSC thermogram substantially as shown in Figure 3.

9. The polymorph of any one of claims 1-8, characterized by a triclinic crystal system with a *P*1 space group.

10. The polymorph of claim 9, characterized by unit cell dimensions, at a temperature of 100 Kelvin, of a = 6.74 ± 0.10 Å, b = 12.74 ± 0.10 Å, c = 15.99 ± 0.10 Å, α = 83.9 ± 1.0°, β = 80.0 ± 1.0°, and γ = 75.1 ± 1.0°.

11. The polymorph of any one of claims 1-10, wherein the polymorph is substantially free of other solid forms of Compound I.

12. A composition comprising a Form B polymorph according to any one of claims 1-11, wherein the composition is at least 90% Form B by weight.

13. Form C polymorph of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione.

14. The polymorph of claim 13, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least three peaks selected from the group consisting of 7.5, 13.8, 16.4, 17.4, 20.1, and 27.7 ˚2θ ± 0.2 ˚2θ.

15. The polymorph of claim 13, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 7.5, 16.4, and 20.1 ˚2θ ± 0.2 ˚2θ.

16. The polymorph of claim 13, characterized by one or more of the following:

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 7.5, 13.8, 16.4, and 20.1 ˚2θ ± 0.2 ˚2θ

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 7.5, 16.4, 20.1 and 27.7 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 7.5, 13.8, 16.4, 17.4, 20.1, and 27.7 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least five peaks selected from the group consisting of 7.5, 8.2, 13.8, 15.2, 15.6, 16.4, 17.4, 20.1, 22.3, and 27.7 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 7.5, 8.2, 13.8, 15.2, 15.6, 16.4, 17.4, 20.1, 22.3, and 27.7 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 7.5, 8.2, 13.8, 14.7, 15.2, 15.6, 16.4, 17.4, 17.8, 20.1, 20.5,

20.9, 21.2, 21.7, 22.3, 22.6, 23.0, 23.5, 24.5, 25.0, 25.6, 26.7, 27.7, 28.2, 28.5, 29.4, 29.9, 30.8, and 31.7 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, substantially as shown in Figure 6.

17. The polymorph of any one of claims 13-16, characterized by a DSC thermogram comprising an endotherm onset at about 306 °C.

18. The polymorph of claim 17, characterized by a DSC thermogram substantially as shown in Figure 7.

19. The polymorph of any one of claims 13-18, wherein the polymorph is substantially free of other solid forms of Compound I.

20. A composition comprising a Form C polymorph according to any one of claims 13-19, wherein the composition is at least 90% Form C by weight.

21. Form D polymorph of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione.

22. The polymorph of claim 21, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least three peaks selected from the group consisting of 11.1, 15.0, 18.3, 19.8, 20.2, 22.5, and 25.9 ˚2θ ± 0.2 ˚2θ.

23. The polymorph of claim 21, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 11.1, 15.0, and 25.9 ˚2θ ± 0.2 ˚2θ.

24. The polymorph of claim 21, characterized by one or more of the following:

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 11.1, 15.0, 19.8 and 25.9 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 11.1, 15.0, 18.3, 19.8, 20.2, 22.5, and 25.9 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least five peaks selected from the group consisting of 11.1, 15.0, 18.3, 19.8, 20.2, 22.5, 23.0, 25.0, 25.9, and 28.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 11.1, 15.0, 18.3, 19.8, 20.2, 22.5, 23.0, 25.0, 25.9, and 28.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 11.1, 14.0, 15.0, 15.4, 18.3, 19.3, 19.8, 20.2, 20.7, 22.5, 23.0, 25.0, 25.9, 26.7, 27.4, 28.2, 30.1, and 31.8 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, substantially as shown in Figure 9.

25. The polymorph of any one of claims 21-24, wherein the polymorph is substantially free of other solid forms of Compound I.

26. A composition comprising a Form D polymorph according to any one of claims 21-25, wherein the composition is at least 90% Form D by weight.

27. Form E polymorph of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione.

28. The polymorph of claim 27, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least three peaks selected from the group consisting of 4.1, 8.6, 16.5, 17.7, and 23.2 ˚2θ ± 0.2 ˚2θ.

29. The polymorph of claim 27, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 8.6, 17.7, and 23.2 ˚2θ ± 0.2 ˚2θ.

30. The polymorph of claim 27, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 4.1, 8.6, and 16.5 ˚2θ ± 0.2 ˚2θ.

31. The polymorph of claim 27, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 4.1, 8.6, and 17.7 ˚2θ ± 0.2 ˚2θ.

32. The polymorph of claim 27, characterized by one or more of the following:

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 8.6, 16.5, 17.7, and 23.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 8.6, 17.7, 22.3, and 23.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 4.1, 8.6, 16.5, 17.7, 22.3, and 23.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least five peaks selected from the group consisting of 4.1, 7.2, 8.6, 13.6, 15.7, 16.5, 17.7, 19.3, 22.3, and 23.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 4.1, 7.2, 8.6, 13.6, 15.7, 16.5, 17.7, 19.3, 22.3, and 23.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 4.1, 7.2, 7.9, 8.6, 13.6, 14.3, 15.3, 15.7, 16.1, 16.5, 17.3, 17.7, 18.3, 18.7, 19.3, 21.1, 21.7, 22.3, 23.2, 26.4, 27.6, 28.5, 28.8, and 30.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising a peak at 4.1 ˚2θ ± 0.2 ˚2θ and at least two peaks selected from the group consisting of 8.6, 16.5, 17.7, and 23.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, substantially as shown in Figure 11.

33. The polymorph of any one of claims 27-32, characterized by a DSC thermogram comprising an endotherm onset at about 304 °C.

34. The polymorph of claim 33, characterized by a DSC thermogram substantially as shown in Figure 12.

35. The polymorph of any one of claims 27-34, characterized by a monoclinic crystal system with a *C*2 space group.

36. The polymorph of claim 35, characterized by unit cell dimensions, at a temperature of 302 Kelvin, of a = 24.75 ± 0.10 Å, b = 6.73 ± 0.10 Å, c = 21.64 ± 0.10 Å, α = 90.0 ± 1.0°, β = 95.7 ± 1.0°, and γ = 90.0 ± 1.0°.

37. The polymorph of any one of claims 27-36, wherein the polymorph is substantially free of other solid forms of Compound I.

38. A composition comprising a Form E polymorph according to any one of claims 27-37, wherein the composition is at least 90% Form E by weight.

39. Form F polymorph of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione.

40. The polymorph of claim 39, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least three peaks selected from the group consisting of 6.8, 9.0, 13.7, 14.2, and 20.3 ˚2θ ± 0.2 ˚2θ.

41. The polymorph of claim 39, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 9.0, and 14.2 ˚2θ ± 0.2 ˚2θ.

42. The polymorph of claim 39, characterized by an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 9.0, and 20.3 ˚2θ ± 0.2 ˚2θ.

43. The polymorph of claim 39, characterized by one or more of the following:

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 9.0, 13.7, and 14.2 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 9.0, 14.2, and 20.3 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 9.0, 13.7, 14.2, and 20.3 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 9.0, 13.7, 14.2, 20.3, and 22.9 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising at least five peaks selected from the group consisting of 6.8, 9.0, 13.7, 14.2, 15.7, 17.4, 17.8, 18.8, 20.3, and 22.9 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 9.0, 13.7, 14.2, 15.7, 17.4, 17.8, 18.8, 20.3, and 22.9 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, comprising peaks at 6.8, 7.5, 9.0, 11.2, 13.7, 14.2, 15.2, 15.7, 16.9, 17.4, 17.8, 18.1, 18.8, 19.5, 19.9, 20.3, 20.6, 22.4, 22.9, 23.6, 24.1, 25.1, 27.4, 28.1, 28.5, 29.2, 30.1, and 30.7 ˚2θ ± 0.2 ˚2θ.

an X-ray powder diffraction pattern, obtained by irradiation with Cu-Kα at room temperature, substantially as shown in Figure 14.

44. The polymorph of any one of claims 39-43, wherein the polymorph is substantially free of other solid forms of Compound I.

45. A composition comprising a Form F polymorph according to any one of claims 39-44, wherein the composition is at least 90% Form F by weight.

46. A pharmaceutical composition comprising a polymorph of Form B, C, D, E or F, or any combination thereof, according to any one of the preceding claims, and a pharmaceutically acceptable excipient.

47. The pharmaceutical composition of claim 46, comprising a Form B polymorph according to any one of claims 1-11 or a composition according to claim 12.

48. Use of a polymorph or composition of any one of the preceding claims in the manufacture of a medicament for treating a cardiac disease or disorder .49.The use of claim 48, wherein the cardiac disease or disorder is hypertrophic cardiomyopathy (HCM), heart failure with preserved ejection fraction (HFpEF), or left ventricular hypertrophy.

50. The use of claim 48 or 49, wherein the polymorph or composition is a Form B polymorph according to any one of claims 1-11 or a composition according to claim 12.

51. The polymorph or composition of any one of the preceding claims for use in therapy.